ginkgolide B

ginkgolide B

Alternative pharmacology
A chemical extracted from the ginkgo tree (Ginkgo biloba), which is a platelet-activating factor (PAF) receptor antagonist that inhibits neutrophil degranulation and superoxide production in vitro, inhibits bronchoconstriction in patients with asthma, is neuroprotective after oral administration and is of potential use in treating circulatory defects in the elderly.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Our previous studies showed that the PAFR inhibitor ginkgolide B reduced the plaque area and vascular inflammation in apolipoprotein E-deficient mice [18].
Ginkgolide B is a Ginkgo biloba leaf extract that has been identified as a natural PAFR antagonist [23].
* terpene lactones (15.4%) composed of 6.94% bilobalide, 3.74% ginkgolide A and 1.62% ginkgolide B, 3.06% ginkgolide C;
Other topics include the distribution of selenium and zinc, monocyte survival through defines intracellular pathways, insulin expression in rat testes and a new transcript splice variant of the human glacocorticoid receptor, while chemoprevention topics include the effects of wagonin, ginkgolide B, and phenolic phytochemicals.
Ginkgolide B, a component of Ginkgo biloba, is a known platelet aggregation factor antagonist, and the herb, alone or with analgesics, has been associated with intracranial bleeding events.
The primary active principles in ginkgo are flavone glycosides and the terpene lactones bilobalide and certain ginkgolides, particularly ginkgolide B. Effects include inhibition of platelet activating factor and reduction of erythrocyte aggregation (Br.
Neither GBE (up to 1000 mg/kg) nor ginkgolide B (up to 140 mg/kg), a platelet-activating factor antagonist, influenced blood coagulation parameters.
One of the proposed mechanisms by which GBE could cause bleeding is via the action of ginkgolide B, a constituent of GBE that is reported to be a platelet-activating factor (PAF) antagonist (Smith et al.
Ginkgolide B is thought to be neuroprotective and antithrombotic.
Louis, USA: ginkgolide A, 90% purity, ginkgolide B, 90% purity; bilobalide, 95% purity.
Standard Ginkgo terpenes, ginkgolide A, ginkgolide B and bilobalide, and standardized Ginkgo leaf extracts (Tanakan, Ispen-Beaufour), at a final concentration of 40 [micro]g each, were also investigated for antitumor activity (Fig.
Under the chosen experimental conditions, PAF-mediated aggregation of human platelets was half-maximally inhibited by ginkgolide B, A, C and J at concentrations of 2.5, 15.8, 29.8 and 43.5 [micro]g/ml, respectively.